Novartis International AG http://www.novartis.com Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Phase III Novartis data show potential benefit of Afinitor® plus Sandostatin® LAR® in patients with advanced neuroendocrine tumors 2010-10-11T10:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1450718.shtml Novartis drug Tasigna® recommended for approval in European Union to treat patients with newly diagnosed Ph+ chronic myeloid leukemia 2010-09-24T15:07:15 CET http://www.novartis.com/newsroom/media-releases/en/2010/1446754.shtml Novartis drug SOM230 is first medical therapy to show efficacy in a Phase III trial in Cushing's disease, a debilitating hormonal disorder 2010-09-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1445885.shtml Novartis JAK inhibitor provides marked and durable clinical benefits in patients with myelofibrosis, a rare, life-threatening blood cancer 2010-09-15T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1444522.shtml Novartis drug Tasigna® approved in Switzerland after fast-track review for treatment of patients with newly diagnosed Ph+ CML 2010-08-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1440842.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Phase III study shows Novartis drug Afinitor® more than doubles time without tumor growth in advanced pancreatic NET patients 2010-07-01T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428793.shtml FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Glivec® 2010-06-18T00:15:56 CET http://www.novartis.com/newsroom/media-releases/en/2010/1424982.shtml Study at ASCO shows Novartis drug Afinitor® first to shrink SEGA brain tumors in children and adults with tuberous sclerosis 2010-06-05T23:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421888.shtml Adding Novartis drug Zometa® to chemotherapy significantly improved overall survival in study of newly diagnosed multiple myeloma patients 2010-06-05T14:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421887.shtml New data at ASCO show Novartis drug Tasigna® surpasses Glivec® in slowing disease progression for newly diagnosed CML patients 2010-06-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421566.shtml Pivotal Phase III trial of Novartis drug Afinitor® met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors 2010-06-03T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1421290.shtml Data at ASCO show promise of Novartis drugs for patients with life-threatening diseases like CML, multiple myeloma and breast cancer 2010-06-02T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1420819.shtml Novartis Phase III trial examining EPO906 (patupilone) for patients with advanced ovarian cancer failed to meet primary endpoint 2010-05-27T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1419057.shtml Novartis healthcare portfolio generates strong growth in first quarter of 2010, progress on delivering innovation, growth and productivity 2010-04-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1405499.shtml Novartis drug Tasigna® receives FDA priority review for newly diagnosed patients with early-stage chronic myeloid leukemia 2010-02-19T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1386313.shtml Novartis achieves record results in 2009 as momentum from recently launched products drives growth across its entire healthcare portfolio 2010-01-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1377026.shtml Three new Novartis medicines approved in Japan for patients with type 2 diabetes, high blood pressure and advanced kidney cancer 2010-01-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1375090.shtml Novartis set to sustain its leading global position in oncology with portfolio targeting various tumors and life-threatening diseases 2009-12-09T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1359994.shtml Novartis Tasigna® trial shows superior results to Glivec® in patients with early-stage chronic myeloid leukemia 2009-12-08T14:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1359764.shtml Basel, December 8, 2009 - In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1]. Novartis gains rights to two oral targeted investigational therapies focusing on patients with life-threatening blood disorders and cancers 2009-11-25T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1357027.shtml Basel, November 25, 2009 - Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options. Novartis delivers strong new product momentum and operational performance in first nine months of 2009 2009-10-22T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1349248.shtml Basel, October 22, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased with our strong underlying performance, led by the momentum of our Pharmaceuticals business, outpacing the competition and benefiting from innovative product growth rejuvenating the portfolio. Our investments in R&D show excellent results, with many key approvals in 2009, most notably the anti-cancer therapy Afinitor and the biotechnology medicine Ilaris. Deliveries of H1N1 pandemic flu vaccines are underway as Novartis works at full capacity to meet public health demands. The Sandoz generics business also made good progress, coupled with a turnaround in the US. We expect record full-year underlying results based on the significant progress to date in 2009. Novartis drug Tasigna® meets primary endpoint in pivotal trial against Glivec® as first-line treatment in chronic myeloid leukemia patients 2009-10-20T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1348449.shtml Study details Results in The New England Journal of Medicine confirm Novartis drug Femara® is superior to tamoxifen after breast cancer surgery 2009-08-19T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1335978.shtml Basel, August 19, 2009 - Newly published data in The New England Journal of Medicine affirm five-year upfront use of Femara® (letrozole) following surgery as an optimal treatment approach versus tamoxifen for postmenopausal women with early stage breast cancer (hormone-receptor positive). Afinitor® approved in EU as first treatment proven to benefit patients with advanced kidney cancer after failure of targeted therapy 2009-08-06T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1332932.shtml Basel, August 6, 2009 - The European Commission (EC) has approved Afinitor® (everolimus) tablets for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy. Novartis delivers strong operational performance in the first half of 2009 driven by sustained Pharmaceuticals innovation 2009-07-16T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329090.shtml Basel, July 16, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: I am pleased that our pharmaceuticals business continues to deliver double-digit underlying growth, driven by the strong momentum of our recently launched products. Our pipeline continues to deliver a steady stream of innovative medicines. In the first six months of 2009 we have introduced our new anti-cancer therapy Afinitor in the US and gained first approval for llaris as a new biologic therapy for auto-inflammatory diseases. We are advancing well in our efforts to rapidly produce and commercialize a vaccine against the H1N1 virus, with clinical trials set to begin in July. We continue to expect record underlying results in constant currencies based on innovation and productivity initiatives. Afinitor® and Sandostatin® LAR® Phase II data show advanced pancreatic NET patients remain progression-free for nearly 17 months 2009-06-24T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1324661.shtml Basel, June 24, 2009 - New data demonstrate that treatment with Afinitor® (everolimus) Tablets in combination with Sandostatin® LAR® (octreotide acetate suspension for injection) and Afinitor monotherapy may have the potential to control tumor growth in patients with advanced pancreatic neuroendocrine tumors (NET). These results will be presented at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Afinitor® Phase II data show positive results for patients with multiple types of lymphoma, leading to Phase III trial 2009-06-08T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1320856.shtml Basel, June 8, 2009 - New data show that Afinitor® (everolimus) Tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease[1]. Based on results from this study and other early-stage research, Novartis has initiated a Phase III trial in the most common NHL, diffuse large B-cell lymphoma (DLBCL). Tasigna® shows rapid and deep responses in newly diagnosed patients with a form of chronic myeloid leukemia 2009-06-05T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1320149.shtml Basel, June 5, 2009 - New data show that at 12 months newly diagnosed patients taking Tasigna® (nilotinib) to treat a life-threatening form of chronic myeloid leukemia (CML) had rapid responses and a deep reduction in the amount of the abnormal protein that causes this disease. Afinitor® recommended for use in the European Union for patients with advanced kidney cancer 2009-05-29T18:24:32 CET http://www.novartis.com/newsroom/media-releases/en/2009/1318767.shtml Important safety information Data on more than 15 Novartis Oncology compounds at ASCO highlight progress toward targeted therapies for diverse tumor types 2009-05-28T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1318019.shtml Basel, May 28, 2009 - Novartis announced today that data on more than 15 compounds in its robust oncology portfolio will be included at the 2009 American Society of Clinical Oncology (ASCO) annual meeting. These studies provide new research on multiple tumor types and rare cancers. Sandoz to acquire EBEWE Pharma specialty generics business, improving access for patients worldwide to injectable cancer drugs 2009-05-20T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1316498.shtml Basel, May 20, 2009 - Novartis has signed a definitive agreement to acquire the specialty generic injectables business of EBEWE Pharma, providing Sandoz - the Group's generic pharmaceuticals division - an opportunity to create a strong global platform for future growth while improving access for patients worldwide to many generic oncology medicines. Scientists who developed Novartis Coartem® and Glivec® receive 2009 ''European Inventor of the Year'' awards 2009-05-13T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1314511.shtml Basel, May 13, 2009 - Scientists who created life-saving Novartis drugs were recognized as 2009 European Inventors of the Year by the European Commission and the European Patent Office. The Inventor of the Year award honors individuals who have made a defining and lasting contribution to technical progress in Europe and helped strengthen the European economy. Glivec® approved in EU as first post-surgery therapy to reduce risk of cancer returning in patients with aggressive gastrointestinal tumors 2009-05-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1311895.shtml Study details Pharmaceuticals delivers strong underlying growth in first quarter of 2009 as Novartis continues to rejuvenate product portfolio 2009-04-23T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1329178.shtml Afinitor® approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib 2009-03-30T21:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1301801.shtml Basel, March 30, 2009 - Novartis announced today that Afinitor® (everolimus) tablets has been approved by the US Food and Drug Administration (FDA) for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent® (sunitinib)* or Nexavar® (sorafenib)**. Glivec® recommended for use in Europe as first post-surgery treatment for gastrointestinal stromal tumors (GIST) 2009-03-19T17:43:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1299087.shtml Basel, March 19, 2009 - Novartis has received a positive opinion supporting European Union (EU) approval of Glivec® (imatinib)* as a post-surgery treatment for patients at significant risk of relapse following removal of gastrointestinal stromal tumors (GIST). Glivec® substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors, The Lancet reports 2009-03-18T23:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1298635.shtml Basel, March 18, 2009 - Data published today online and in an upcoming print issue of The Lancet show that Glivec®* (imatinib), when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo. Zometa® reduces risk of breast cancer recurrence in premenopausal women, study in The New England Journal of Medicine reports 2009-02-11T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1289425.shtml Study details Novartis increases dividend by 25% based on strong 2008 results from strategic healthcare portfolio 2009-01-28T06:59:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1285325.shtml Basel, January 28, 2009 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis, said: Thanks to successful innovation and a leading market position of our healthcare business portfolio, Novartis achieved a strong performance in 2008. Pharmaceuticals returned to dynamic growth and gained market share in the second half of the year, while Vaccines and Diagnostics continued its double-digit growth. Recently launched pharmaceutical products contributed USD 2.9 billion in sales in 2008 further rejuvenating our portfolio, and we submitted 14 major new products filings that underpin our innovation power. Organic growth was complemented by several acquisitions and strategic investments, the most important being the acquisition of a 25% share of Alcon. Novartis anticipates another year of record results in 2009, continuing on its path of sustainable growth. New study first to confirm Sandostatin® LAR® controls tumor growth in patients with rare gastrointestinal tumors 2009-01-14T00:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1281971.shtml Basel, January 13, 2009 - Sandostatin® LAR® (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut, according to interim data presented today at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology. Afinitor® Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments 2009-01-14T00:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2009/1281970.shtml Basel, January 13, 2009 - Data released today show Afinitor® (also known as RAD001, everolimus) halted tumor growth in 55% of patients with advanced gastric cancer, a condition for which there are limited treatment options. In addition, 45% of patients in the study demonstrated some tumor shrinkage[1]. Glivec receives US approval as first treatment to reduce risk of cancer returning in patients with gastrointestinal stromal tumors 2008-12-20T02:14:19 CET http://www.novartis.com/newsroom/media-releases/en/2008/1279094.shtml Basel, December 19, 2008 - Novartis announced today that Glivec® (imatinib)* has been approved by the US Food and Drug Administration (FDA) for the post-surgery treatment of adult patients following complete surgical removal of Kit (CD117)-positive gastrointestinal stromal tumors (GIST). Afinitor® shows potential to reverse resistance to Herceptin®[*] in metastatic breast cancer patients, leading to Phase III trial 2008-12-13T00:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1277244.shtml Basel, December 12, 2008 - New data from two early clinical studies show that Afinitor® (everolimus) may overcome resistance to Herceptin® (trastuzumab)[*] in women with HER2- positive metastatic breast cancer[1],[2]. These results support the initiation of a Phase III clinical trial program to fully explore the potential of Afinitor, also known as RAD001, in breast cancer. New data show Zometa® enhances impact of chemotherapy on reducing breast tumor size 2008-12-11T21:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1276910.shtml Basel, December 11, 2008 - New data released today demonstrate that the addition of Zometa® (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease. Femara® first aromatase inhibitor to indicate survival benefit versus tamoxifen when taken for five years after breast cancer surgery 2008-12-11T16:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1276719.shtml Basel, December 11, 2008 - New long-term data from a major international breast cancer study reports that postmenopausal woman with hormone receptor-positive early-stage breast cancer who took Femara® (letrozole) for five years following surgery had a 13% (P=0.08) reduced risk of death, when compared with tamoxifen[1]. Exjade® benefits chronically transfused patients by significantly reducing toxic iron that can damage key organs, according to landmark trial 2008-12-09T00:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1275815.shtml Basel, December 9, 2008 - New data from the largest prospective trial in iron chelation demonstrate the efficacy and safety of Exjade® (deferasirox) in treating chronic transfusional iron overload, a potentially life-threatening condition for patients who have had multiple blood transfusions to treat underlying anemias, including beta-thalassemia and myelodysplastic syndromes (MDS). Tasigna® demonstrates rapid response as initial therapy in life-threatening form of leukemia 2008-12-08T22:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1275790.shtml Study results More than 200 abstracts at ASH and SABCS reveal potential compelling patient benefits from Novartis Oncology current and pipeline therapies 2008-12-04T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2008/1275058.shtml Basel, December 4, 2008 - More than 200 abstracts from therapies across the Novartis Oncology portfolio will be presented at two December medical congresses, providing new data and profiling potential patient benefits from ongoing collaboration with the oncology community. Novartis réalise, au deuxième trimestre, une excellente performance financière, soutenue par l'essor grandissant de l'innovation 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1431808.shtml Novartis: excellente performance opérationnelle au premier semestre 2009, entraînée par les innovations soutenues de Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2009/1329097.shtml Bâle, le 16 juillet 2009 - En commentant les résultats, le DrDaniel Vasella, Président et Administrateur délégué de Novartis a déclaré: «Je suis heureux de voir que nos activités pharmaceutiques continuent de progresser au rythme d'une croissance sous-jacente à deux chiffres, sous la forte impulsion des produits lancés récemment. Tandis que notre pipeline émet un flux continu de médicaments innovants. Au cours des six premiers mois de 2009, nous avons lancé Afinitor, notre nouveau traitement anticancer aux Etats-Unis où nous avons également obtenu une première homologation pour Ilaris, un nouveau traitement biologique pour un groupe de maladies auto-inflammatoires. Nous avançons rapidement vers la production et la commercialisation d'un vaccin contre le virus H1N1, dont les essais cliniques commenceront en juillet. Nous prévoyons toujours de réaliser des résultats sous-jacents records en monnaies constantes, grâce à l'innovation et aux gains de productivité». Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Novartis erzielt 2009 Rekordergebnisse - Neu eingeführte Produkte erweisen sich als Wachstumstreiber 2010-01-26T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1377020.shtml Novartis verzeichnet in den ersten neun Monaten 2009 eine kräftige Dynamik der neuen Produkte und erzielt eine starke operative Performance 2009-10-22T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1349244.shtml Neun Monate bis 30. September Novartis erzielt im ersten Halbjahr 2009 eine starke operative Performance - dank der anhaltenden Innovationskraft der Division Pharmaceuticals 2009-07-16T06:59:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2009/1329092.shtml Erstes Halbjahr Neue Daten zeigen: Zometa® verbessert Wirkung der Chemotherapie in der Tumor-Reduktion des Mammakarzinoms 2008-12-11T21:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2008/1276918.shtml Basel, 11. Dezember 2008 - Die neuen Daten, die heute präsentiert wurden, zeigen, dass Zometa® (Zoledronsäure) bei Frauen mit frühem Brustkrebs, zusätzlich zur neo-adjuvanten Chemotherapie gegeben, die Größe von Brustkrebstumoren effektiver reduziert als eine alleinige Chemotherapie. Femara® ist der erste Aromatasehemmer, der im Vergleich zu Tamoxifen bei Einnahme über fünf Jahre nach Brustkrebsoperation auf Überlebensvorteil hinweist 2008-12-11T16:45:00 CET http://www.novartis.com/newsroom/media-releases/de/2008/1276726.shtml Basel, 11. Dezember 2008 - Neue Langzeitdaten aus einer führenden internationalen Brustkrebsstudie zeigen, dass postmenopausale Frauen mit Hormonrezeptor-positivem primärem Mammakarzinom, die direkt nach Operation über fünf Jahre Femara® (Letrozol) einnahmen, ein um 13% (p=0,08) reduziertes Mortalitätsrisiko im Vergleich zu Tamoxifen aufweisen[1].